12.3155.99% ( -0.785 )
Trading: Nov 16, 11:46:50 (EDT)Financials
Q2 FY2026 EarningsQ3 FY26 results featured a significant top-line beat with revenue of $11.35M vs. $8.29M expected (+36.9% variance), driven by accelerating AI discovery collaborations. While GAAP EPS of -$8.52 significantly missed the -$0.77 consensus due to a $10.4M one-time non-cash charge related to convertible note fair value adjustments pre-IPO, operational performance remained robust. Strong execution in clinical milestones and the successful $156M IPO in October post-quarter end have bolstered the pro-forma cash position to $455M, providing a substantial runway for registrational trials in 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Iambic Therapeutics(IAM) the Revenue is 6.377 M (+224.7%);the EBIT is -26.76 M (-50%);the EPS is -1.12 (-45.13%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.01B224.67%
----
----
EBIT
-0.03B50.00%
----
----
EPS
-1.117945.13%
----
----
Upcoming earnings report - FY2026 Q3 Earning Release
Available dateDec 23, 2026
Estimate Revenue8.292 M
Estimate EBIT-31.05 M
Estimate EPS-0.765
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly
